Browse hierarchy: [Gastroenterology, Urology (GU)](/submissions/GU) → [Subpart F — Therapeutic Devices](/submissions/GU/subpart-f%E2%80%94therapeutic-devices) → [21 CFR 876.5940](/submissions/GU/subpart-f%E2%80%94therapeutic-devices/876.5940) → QTN — Orally Ingested Transient Device For Constipation

# QTN · Orally Ingested Transient Device For Constipation

_Gastroenterology, Urology · 21 CFR 876.5940 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QTN

## Overview

- **Product Code:** QTN
- **Device Name:** Orally Ingested Transient Device For Constipation
- **Regulation:** [21 CFR 876.5940](/submissions/GU/subpart-f%E2%80%94therapeutic-devices/876.5940)
- **Device Class:** 2
- **Review Panel:** [Gastroenterology, Urology](/submissions/GU)

## Identification

An orally ingested transient device for constipation is an electric swallowable capsule that naturally passes through the gastrointestinal tract for the treatment of constipation. The Vibrant System is indicated for the treatment of adults with chronic idiopathic constipation who have not experienced relief of their bowel symptoms by using laxative therapies at the recommended dosage for at least one month.

## Classification Rationale

Class II (special controls). The device is granted under the De Novo process, with risks mitigated by general controls and the identified special controls.

## Special Controls

In combination with the general controls of the FD&C Act, an orally ingested transient device for constipation is subject to the following special controls:

## Recent Cleared Devices (3 of 3)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K232830](https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QTN/K232830.md) | Vibrant System | Vibrant, Ltd. | Dec 8, 2023 | SESE |
| [K223031](https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QTN/K223031.md) | Vibrant System | Vibrant, Ltd. | Jan 13, 2023 | SESE |
| [DEN210052](https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QTN/DEN210052.md) | Vibrant System | Vibrant, Ltd. | Aug 26, 2022 | DENG |

## Top Applicants

- Vibrant, Ltd. — 3 clearances

---

**Source:** [https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QTN](https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QTN)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com